The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo

被引:308
作者
Ashley, EA [1 ]
Powers, J [1 ]
Chen, M [1 ]
Kundu, R [1 ]
Finsterbach, T [1 ]
Caffarelli, A [1 ]
Deng, A [1 ]
Eichhorn, J [1 ]
Mahajan, R [1 ]
Agrawal, R [1 ]
Greve, J [1 ]
Robbins, R [1 ]
Patterson, AJ [1 ]
Bernstein, D [1 ]
Quertermous, T [1 ]
机构
[1] Stanford Univ, Donald W Reynolds Cardiovasc Res Ctr, Div Cardiovasc Med, Falk CVRC, Stanford, CA 94305 USA
关键词
apelin; APJ; angiotensin; heart failure; pressure-volume hemodynamics;
D O I
10.1016/j.cardiores.2004.08.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The endogenous peptide apelin is differentially regulated in cardiovascular disease but the nature of its role in cardiac function remains unclear. Methods: We investigated the functional relevance of this peptide using ECG and respiration gated magnetic resonance imaging, conductance catheter pressure-volume hemodynamic measurements, and echocardiography in vivo. In addition, we carried out histology and immunohistochemistry to assess cardiac hypertrophy and to localize apelin and APJ in the adult and embryonic mouse heart. Results: Intraperitoneal injection of apelin (300 mug/kg) resulted in a decrease in left ventricular end diastolic area (pre: 0.122 +/- 0.007; post: 0.104 +/- 0.005 cm(2), p = 0.006) and an increase in heart rate (pre: 537 +/- 20; post: 559 +/- 19 beats per minute, p = 0.03). Hemodynamic measurements revealed a marked increase in ventricular elastance (pre: 3.7 +/- 0.9; post: 6.5 +/- 1.4 mm Hg/RVU, p = 0.018) and preload recruitable stroke work (pre: 27.4 +/- 8.0; post: 51.8 +/- 3.1,p = 0.059) with little change in diastolic parameters following acute infusion of apelin. Chronic infusion (2 mg/kg/day) resulted in significant increases in the velocity of circumferential shortening (baseline: 5.36 +/- 0.401; 14 days: 6.85 +/- 0.358 circ/s, p = 0.049) and cardiac output (baseline: 0.142 +/- 0.019; 14 days: 0.25 +/- 0.019 l/min, p = 0.001) as determined by 15 MHz echocardiography. Post-mortem corrected heart weights were not different between apelin and saline groups (p = 0.5) and histology revealed no evidence of cellular hypertrophy in the apelin group (nuclei per unit area, p = 0.9). Immunohistochemistry studies revealed APJ staining of myocardial cells in all regions of the adult mouse heart. Antibody staining, as well as quantitative real time polymerase chain reaction identified expression of both APJ and apelin in embryonic myocardium as early as embryonic day 13.5. Conclusions: Apelin reduces left ventricular preload and afterload and increases contractile reserve without evidence of hypertrophy. These results associate apelin with a positive hemodynamic profile and suggest it as an attractive target for pharmacotherapy in the setting of heart failure. (C) 2004 European Society of Cardiology. Published by Elsevier B.V.
引用
收藏
页码:73 / 82
页数:10
相关论文
共 32 条
[1]  
Bers D.M., 2001, Excitation-Contraction Coupling and Cardiac Contractile Force, V2th
[2]   Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction [J].
Chen, MM ;
Ashley, EA ;
Deng, DXF ;
Tsalenko, A ;
Deng, A ;
Tabibiazar, R ;
Ben-Dor, A ;
Fenster, B ;
Yang, E ;
King, JY ;
Fowler, M ;
Robbins, R ;
Johnson, FL ;
Bruhn, L ;
McDonagh, T ;
Dargie, H ;
Yakhini, Z ;
Tsao, PS ;
Quertermous, T .
CIRCULATION, 2003, 108 (12) :1432-1439
[3]   Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats [J].
Cheng, X ;
Cheng, XS ;
Pang, CCY .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 470 (03) :171-175
[4]   INOTROPIC THERAPY FOR HEART-FAILURE - AN UNFULFILLED PROMISE [J].
CURFMAN, GD .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (21) :1509-1510
[5]  
De Falco M, 2002, IN VIVO, V16, P333
[6]   Cloning, pharmacological characterization and brain distribution of the rat apelin receptor [J].
De Mota, N ;
Lenkei, Z ;
Llorens-Cortès, C .
NEUROENDOCRINOLOGY, 2000, 72 (06) :400-407
[7]   Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release [J].
De Mota, N ;
Goazigo, ARL ;
El Messari, S ;
Chartrel, N ;
Roesch, D ;
Dujardin, C ;
Kordon, C ;
Vaudry, H ;
Moos, FO ;
Llorens-Cortes, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (28) :10464-10469
[8]   Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing β2-adrenergic receptors in the heart [J].
Du, XJ ;
Gao, XM ;
Wang, BH ;
Jennings, GL ;
Woodcock, EA ;
Dart, AM .
CARDIOVASCULAR RESEARCH, 2000, 48 (03) :448-454
[9]   Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: A randomized, double-blind, placebo-controlled study [J].
Elis, A ;
Bental, T ;
Kimchi, O ;
Ravid, M ;
Lishner, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (06) :682-685
[10]   Altered calcium handling is critically involved in the cardiotoxic effects of chronic β-adrenergic stimulation [J].
Engelhardt, S ;
Hein, L ;
Dyachenkow, V ;
Kranias, EG ;
Isenberg, G ;
Lohse, MJ .
CIRCULATION, 2004, 109 (09) :1154-1160